University of California, Irvine Medical Center
Orange, California, 92868, United States
NCT Number: NCT01215721
Prostate cancer is the most common non-cutaneous malignancy in men and is the 2nd leading cause of death from cancer in men. Radical prostatectomy is one of the treatment options available for organ-confined disease. Over 100,000 radical prostatectomies cases (total removal of the cancerous prostate by surgery) are performed in the United States yearly. Unfortunately nearly all of the men undergoing surgery report diminished Quality of Life (QOL) scores due in part due to a postoperative incontinence which may require the use of multiple urinary pads per day. Many of these men also report debilitating irritative voiding symptoms of urinary urgency and frequency, and have overall decreased urinary satisfaction scores. Abatement of these symptoms can take up to one year in men, and in 5-20% of patients symptoms may persist for longer periods.
Our recent published findings suggest that instability in the bladder muscle is likely an underlying etiology in postoperative urinary incontinence. This 'Detrusor Muscle' instability results in excess contractions of the urinary bladder ('urgency to urinate'), and can result in the feeling of needing to urinate more frequently. Consistent with this hypothesis of detrusor muscle instability, men with postoperative dribbling had more complaints with urgency, frequency and bother scores when queried with validated questionnaires. We suspect that a transient bladder muscle contraction may overcome the urinary sphincter valve resistance and result in the patient's dribbling of urine.
By treating the bladder muscle instability, we expect improved postoperative continence and improved quality of life in patients after undergoing surgery for total removal of a cancerous prostate. This pilot study will assess the statistical requirements for the number of subjects needed for a fully 'powered' randomized prospective study to fully evaluate whether medications such as solifenacin significantly improve patients' quality of urinary life and improve postoperative urinary incontinence after surgery.
*This study has been modified from the original protocol with the clinicaltrials.gov ID: NCT00581061.
Looking for future studies?
Notify Me18 year and older
Male
Interventional
Not applicable
Orange, California, 92868, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
5 mg daily
Other names: Vesicare (Solifenacin)
Time frame: 12 months
Days to zero pad continence were assessed by patient self-reported Pad free continence declaration card.
University of California, Irvine
Other
Vesicare™ (Solifenacin) in the Treatment of Urinary Incontinence After Radical Prostatectomy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04804839
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Ankara, Turkey (Türkiye)
View Trial DetailsNCT03721029
Erectile Dysfunction, Female Urogenital Diseases
Herlev, Central Region, Denmark
View Trial DetailsNCT04862533
Beta-alanine, Female Urogenital Diseases
Olomouc, Czechia
View Trial DetailsNCT01365182
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
View Trial Details